| Prothena is a clinical-stage neuroscience company. Co. is developing a pipeline of therapeutic candidates for a number of indications and targets. Co.'s partnered programs include prasinezumab (PRX002/RG7935) for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target for the potential treatment of Alzheimer's disease, amyotrophic lateral sclerosis, frontotemporal dementia or other neurodegenerative diseases. Co.'s proprietary programs include PRX004 for the potential treatment of ATTR amyloidosis, and programs that target Amyloid beta for the potential treatment of Alzheimer's disease. We show 32 historical shares outstanding datapoints in our PRTA shares outstanding history coverage, used to compute PRTA market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PRTA market cap history over the course of time is important for investors
interested in comparing PRTA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PRTA versus a peer is one thing; comparing
PRTA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PRTA can fluctuate over the course of history.
With this page we aim to empower investors researching PRTA by allowing them to research the PRTA market cap history.